Trump Sounds Alarm Over Prescription Drug Prices
Trump administration defends Medicare drug price talks in case brought by Novartis
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.
A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...
Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...
New federal legislation would regulate an industry that’s been examined by FactFinder. Senator Jerry Moran, R-Kan., is one of ...
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...
While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...
The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have list prices ranging from $900 to $1,500 for a one-month supply. David Ricks, the CEO of Mounjaro and Zepbound ...
“Governor Maura Healey’s proposal, to increase costs for prescription drugs, is absolutely ‘ill’ advised. Healthcare costs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback